NCT01517555View on ClinicalTrials.gov

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

DRUG

placebo

Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

DRUG

paracetamol

One single dose of 1 g. Tablet

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01517555 - Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter